{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:24:54Z","timestamp":1755217494380,"version":"3.43.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10096-025-05161-1","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:41:27Z","timestamp":1747269687000},"page":"1945-1951","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the clinical impact of targeting lower versus higher serum vancomycin trough: a retrospective study using a desirability of outcome ranking (DOOR) analysis"],"prefix":"10.1007","volume":"44","author":[{"given":"Zong Heng","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean W. X.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley","family":"Palmay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan H.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-F\u00e9lixe","family":"Granger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip W.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Elligsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"issue":"3","key":"5161_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1086\/600877","volume":"49","author":"J Rybak Michael","year":"2009","unstructured":"Rybak Michael J, Lomaestro Ben M, Rotschafer John C, Moellering Robert C, Craig Willam A, Billeter M et al (2009) Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 49(3):325\u2013327. https:\/\/doi.org\/10.1086\/600877","journal-title":"Clin Infect Dis"},{"issue":"11","key":"5161_CR2","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C et al (2020) Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 77(11):835\u2013863. https:\/\/doi.org\/10.1093\/ajhp\/zxaa036","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"5161_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3138\/jammi-2020-0028","volume":"6","author":"JJ Stewart","year":"2021","unstructured":"Stewart JJ, Jorgensen SCJ, Dresser L, Lau TTY, Gin AS, Daniel et al (2021) A Canadian perspective on the revised 2020 ASHP\u2013IDSA\u2013PIDS\u2013SIDP guidelines for vancomycin AUC-based therapeutic drug monitoring for serious MRSA infections. JAMMI 6(1):3\u20139. https:\/\/doi.org\/10.3138\/jammi-2020-0028","journal-title":"JAMMI"},{"issue":"3","key":"5161_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4212\/cjhp.3337","volume":"76","author":"SCJ Jorgensen","year":"2023","unstructured":"Jorgensen SCJ, McIntyre M, Curran J, So M (2023) Vancomycin Therapeutic Drug Monitoring: A Cross-Sectional Survey of Canadian Hospitals. Can J Hosp Pharm 76(3):203\u2013208. https:\/\/doi.org\/10.4212\/cjhp.3337","journal-title":"Can J Hosp Pharm"},{"issue":"4","key":"5161_CR5","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/jac\/dkz531","volume":"75","author":"NH Ma","year":"2020","unstructured":"Ma NH, Walker SAN, Elligsen M, Kiss A, Palmay L, Ho G et al (2020) Retrospective multicentre matched cohort study comparing safety and efficacy outcomes of intermittent-infusion versus continuous-infusion vancomycin. J Antimicrob Chemother 75(4):1038\u20131046. https:\/\/doi.org\/10.1093\/jac\/dkz531","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"5161_CR6","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cmi.2023.05.003","volume":"29","author":"SW Ong","year":"2023","unstructured":"Ong SW, Petersiel N, Loewenthal MR, Daneman N, Tong SY, Davis JS (2023) Unlocking the DOOR\u2014how to design, apply, analyse, and interpret desirability of outcome ranking endpoints in infectious diseases clinical trials. Clin Microbiol Infect 29(8):1024\u201330. https:\/\/doi.org\/10.1016\/j.cmi.2023.05.003","journal-title":"Clin Microbiol Infect"},{"key":"5161_CR7","doi-asserted-by":"publisher","unstructured":"Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup. 2004 Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care 8(4):R204\u2013212. https:\/\/doi.org\/10.1186\/cc2872","DOI":"10.1186\/cc2872"},{"issue":"8","key":"5161_CR8","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/cid\/ciz460","volume":"70","author":"TP Lodise","year":"2020","unstructured":"Lodise TP, Rosenkranz SL, Finnemeyer M, Evans S, Sims M, Zervos MJ et al (2020) The Emperor\u2019s New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE). Clin Infect Dis 70(8):1536\u20131545. https:\/\/doi.org\/10.1093\/cid\/ciz460","journal-title":"Clin Infect Dis"},{"issue":"10","key":"5161_CR9","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/cid\/ciy766","volume":"68","author":"SB Doernberg","year":"2019","unstructured":"Doernberg SB, Tien T, TongPaul M,Dafna Yahav, Davis JS, SYC et al (2019) Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection. Clin Infect Dis 68(10):1691\u20131698. https:\/\/doi.org\/10.1093\/cid\/ciy766","journal-title":"Clin Infect Dis"},{"issue":"1","key":"5161_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4212\/cjhp.v65i1.1101","volume":"65","author":"M Elligsen","year":"2012","unstructured":"Elligsen M, Walker SAN, Simor A, Daneman N (2012) Prospective Audit and Feedback of Antimicrobial Stewardship in Critical Care: Program Implementation, Experience, and Challenges. Can J Hosp Pharm 65(1):31\u201336. https:\/\/doi.org\/10.4212\/cjhp.v65i1.1101","journal-title":"Can J Hosp Pharm"},{"issue":"1","key":"5161_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1186\/s13063-022-06370-1","volume":"23","author":"NA Turner","year":"2022","unstructured":"Turner NA, Zaharoff S, King H, Evans S, Hamasaki T, Lodise T et al (2022) Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial. Trials 23(1):407. https:\/\/doi.org\/10.1186\/s13063-022-06370-1","journal-title":"Trials"},{"key":"5161_CR12","unstructured":"R Core Team (2019) R a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available from: https:\/\/www.R-project.org\/"},{"issue":"1","key":"5161_CR13","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s13104-016-2252-7","volume":"9","author":"S Tongsai","year":"2016","unstructured":"Tongsai S, Koomanachai P (2016) The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysis. BMC Res Notes 9(1):455. https:\/\/doi.org\/10.1186\/s13104-016-2252-7","journal-title":"BMC Res Notes"},{"issue":"6","key":"5161_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3390\/antibiotics13060497","volume":"13","author":"W Yang","year":"2024","unstructured":"Yang W, Zhang K, Chen Y, Fan Y, Zhang J (2024) Is It Still Beneficial to Monitor the Trough Concentration of Vancomycin? A Quantitative Meta-Analysis of Nephrotoxicity and Efficacy. Antibiotics 13(6):497\u2013507. https:\/\/doi.org\/10.3390\/antibiotics13060497","journal-title":"Antibiotics"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05161-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05161-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05161-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T15:05:34Z","timestamp":1754406334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05161-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["5161"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05161-1","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"type":"print","value":"0934-9723"},{"type":"electronic","value":"1435-4373"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}